This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
February 2020
Presentations

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 441
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS591
Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC

HEOR | Urothelial Carcinoma | Abstract 458
Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS595
Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer
Videos
Enfortumab Vedotin | Urothelial Carcinoma | Abstract 441
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma